RPS10

Small ribosomal subunit protein eS10 · P46783 · RPS10 on Sugi Atlas →

3,655 patent compounds predicted against RPS10, 1,914 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPS10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients	PHASE1/PHASE2	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPS10 binder may also engage these)

Protein	Name	Similarity
G1T168	—	1.000	G1T168 →
Q3T0F4	—	1.000	Q3T0F4 →
Q07254	—	1.000	Q07254 →
Q90YR4	—	1.000	Q90YR4 →
P63325	—	1.000	P63325 →
P63326	—	1.000	P63326 →
Q9VB14	—	0.999	Q9VB14 →
Q9VWG3	—	0.999	Q9VWG3 →
O77302	—	0.999	O77302 →
Q962R9	—	0.997	Q962R9 →
Q9NQ39	—	0.995	Q9NQ39 →
O13614	—	0.994	O13614 →
O14112	—	0.993	O14112 →
O77082	—	0.992	O77082 →
P0DKK8	—	0.988	P0DKK8 →
Q9FFS8	—	0.988	Q9FFS8 →
P0DKK9	—	0.987	P0DKK9 →
Q9LTF2	—	0.985	Q9LTF2 →
Q9SW09	—	0.984	Q9SW09 →
B4KF66	—	0.983	B4KF66 →
Q8BGA5	—	0.983	Q8BGA5 →
A0A1D8PI15	—	0.983	A0A1D8PI15 →
Q4PD40	—	0.982	Q4PD40 →
Q0UWT7	—	0.981	Q0UWT7 →
P0CN02	—	0.981	P0CN02 →
P0CN03	—	0.981	P0CN03 →
G0S3T2	—	0.981	G0S3T2 →
B5X574	—	0.981	B5X574 →
Q13601	—	0.981	Q13601 →
P27238	—	0.981	P27238 →